nach oben

Drugs

Erschienen in:

01.12.2004 | Current Opinion

The Role of Olmesartan Medoxomil in the Management of Hypertension

verfasst von: Prof. Dr Thomas Unger, Gordon T. McInnes, Joel M. Neutel, Michael Böhm

Erschienen in: Drugs | Ausgabe 24/2004

Einloggen, um Zugang zu erhalten

Abstract

Intensive blood pressure control is a desirable and obtainable goal in patients with hypertension, according to the most recent treatment guidelines from Europe and the US. Achieving target blood pressure depends on the efficacy of antihypertensive treatment and patient compliance. Olmesartan medoxomil, a non-peptidergic angiotensin AT₁ receptor antagonist, has been shown to be effective and well tolerated. Continuation of initial treatment is higher with AT₁ receptor antagonists than for any other class of antihypertensive drugs. Olmesartan medoxomil may also have end-organ protective effects that provide additional clinical benefit. Optimal blood pressure control may be achieved faster if initial treatment contains the most efficacious and well tolerated antihypertensive drug or drugs. The ongoing European study, known as OLMEBEST (Efficacy and safety of OLMEsartan: reduction of Blood pressure in the treatment of patients suffering from mild to moderate ESsenTial hypertension), will provide important information on the use of olmesartan medoxomil as an initial treatment for hypertension.

MacMahon S. Antihypertensive drag treatment: the potential, expected and observed effects on vascular disease. J Hypertens Suppl 1990 Dec; 8(7): S239–44

Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC7 Report. JAMA 2003 May; 289(19): 2560–722PubMedCrossRef

Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986 Apr; 4(2): 141–56PubMedCrossRef

Meissner I, Whisnant JP, Sheps GS, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999 Sep; 34(3): 466–71PubMedCrossRef

Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003 Jul; 290(2): 199–206PubMedCrossRef

Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001 Mar; 37(3): 869–74PubMedCrossRef

Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001 Nov; 135(9): 825–34PubMed

European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21(6): 1011–53CrossRef

Menard J, Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995 Jul; 9 Suppl.2: S19–23PubMed

10.

Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001 Oct; 38(4): 827–32PubMed

11.

Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerability. Blood Press 1997 Sep; 6(5): 313–7PubMedCrossRef

12.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep; 345(12): 861–9PubMedCrossRef

13.

Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar; 359(9311): 995–1003PubMedCrossRef

14.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep; 345(12): 851–60PubMedCrossRef

15.

Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998 Jul–Aug; 20(4): 671–81PubMedCrossRef

16.

Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001 Dec; 23(12): 1999–2010PubMedCrossRef

17.

Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995 Oct; 285(2): 181–8PubMedCrossRef

18.

Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41(5): 515–27PubMedCrossRef

19.

Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001 Jun; 19(1): S41–8PubMedCrossRef

20.

Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr; 87 Suppl. 8A: 37C–43CPubMedCrossRef

21.

Neutel JM, Elliott WJ, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002 Sep–Oct; 4(5): 325–31CrossRef

22.

Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003 May; 21(2): S43–6PubMed

23.

White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 Suppl. 6: S9–15

24.

Püchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel antiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997; 15: 1809–12PubMedCrossRef

25.

Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001 Sep–Oct; 3(5): 283–91CrossRef

26.

Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2003; 362: 1527–35

27.

Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001 Jun; 19 Suppl. 1: S49–56PubMed

28.

Neutel JM. Optimal blood pressure control: contribution of olmesartan. Presentation at the 13th European Meeting on Hypertension; 2003 Jun 13–17; Milan

29.

Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004 Mar; 17(3): 252–9PubMedCrossRef

30.

Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther 2004; 26 Suppl. A: A21–7PubMedCrossRef

31.

Kannel WB. Framingham Study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995 Sep; 18(3): 181–96PubMedCrossRef

32.

Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996 Jan; 334(1): 13–8PubMedCrossRef

33.

Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002 Jan; 89(2A): 3A–9APubMedCrossRef

34.

Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000 Sep; 36(30): 646–61

35.

Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure: Valsartan Heart Failure Trial Investigators. N Engl J Med 2001 Dec; 345(23): 1667–75PubMedCrossRef

36.

Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003 Aug; 108(6): 684–90PubMedCrossRef

37.

Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003 Jul; 163(13): 1555–65PubMedCrossRef

38.

Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep; 345(12): 870–8PubMedCrossRef

39.

Lithell H, Hansson L, Skoog I, et al. The Study On Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 May; 21(5): 875–86PubMedCrossRef

40.

Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003 May; 14(5): 1212–22PubMedCrossRef

41.

Ohki R, Yamamoto K, Ueno S, et al. Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes. Cardiovasc Drugs Ther 2003 May; 17(3): 231–6PubMedCrossRef

42.

Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr; 87 Suppl. 8A: 33C–6CPubMedCrossRef

43.

Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT₁ receptor antagonist. J Hypertens Suppl 2001 Jun; 19 Suppl. 1: S3–14PubMed

44.

Böhm M. Shortening the way to optimal blood pressure control. Presentation at the 13th European Meeting on Hypertension; 2003 Jun 13–17; Milan

Titel: The Role of Olmesartan Medoxomil in the Management of Hypertension
verfasst von: Prof. Dr Thomas Unger
Gordon T. McInnes
Joel M. Neutel
Michael Böhm
Publikationsdatum: 01.12.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 24/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464240-00002

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Role of Olmesartan Medoxomil in the Management of Hypertension

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 24/2004

Viral Prophylaxis in Organ Transplant Patients

Orlistat

Pregabalin in Painful Diabetic Peripheral Neuropathy

Pregabalin

Pregabalin in Painful Diabetic Peripheral Neuropathy

Pharmacological Cardioversion of Atrial Fibrillation